Windsor, London, UK, 9 January 2026. Cycle Pharmaceuticals Ltd (Cycle) and Inceptua Group (Inceptua) have announced the expansion of their partnership to make NITYR^® (nitisinone) tablets available via a Free Goods Programme for eligible patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU) to include Morocco and Egypt.

HT-1 and AKU are both ultra-rare diseases. HT-1 affects about 1 in 100,000 individuals worldwide,¹ whilst AKU affects 1 in 250,000 to 1 million people worldwide.² 

A Free Goods Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence. 

Cycle has an existing Free Goods Programme for patients with HT-1 and AKU, supported by Inceptua, in countries where NITYR^® is not commercially available or where the local healthcare system is unable to afford this medication. Countries currently included in the programme are Argentina, Bangladesh, Brazil, Chile, Colombia, Dominican Republic, India, Jordan, Mexico, Nigeria, Pakistan, Peru, Sudan, Tunisia, and Turkey. The expansion of the programme will now include Morocco and Egypt.

Cycle Pharmaceuticals is committed to supporting patients on the Free Goods Programme for the duration of their lifetime and to helping patients across the world irrespective of their ability to pay for treatment. The expansion of the programme reflects Cycle’s ongoing commitment to providing broader and fairer access to treatment for eligible patients in countries where access to nitisinone remains limited.  

Stuart Bell, Executive Vice President, Inceptua Early Access said, “Since the NITYR^® Free Goods Programme opened in 2018, many patients around the world have had the opportunity to access a medicine they would otherwise never have been able to access. Given the severity of HT-1 and AKU, such access can be crucial. We are pleased to support Cycle Pharmaceuticals in expanding this programme to allow eligible patients in Morocco and Egypt, with limited treatment options, the opportunity to access NITYR^®.

James Harrison, CEO of Cycle Pharmaceuticals said, “Everyone at Cycle Pharmaceuticals is passionate about supporting patients, so we’re thrilled to be able to extend the NITYR^® Free Goods Programme to more people with HT-1 and AKU. Our ambition is to supply more patients through the NITYR^® Free Goods Programme than through our commercial supply channels. This expansion will help us to achieve that goal.”

Jon Miller, President of The Network of Tyrosinemia Advocates (NOTA) said “At NOTA, we believe every patient living with HT-1 or AKU deserves access to treatment. Seeing this programme grow to include more countries is incredibly encouraging, and we hope patients in Morocco and Egypt, together with their families, receive the care and support they need.”

Requests for access to NITYR^® must be made by a Healthcare Professional (HCP). HCPs can request access for a patient by contacting Inceptua at: access@inceptua.com or calling + 44 20 3910 7670. 

About NITYR^® 

NITYR^® (nitisinone) Tablets are a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase indicated for the treatment of adult and paediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. NITYR^® has been approved for use by the FDA, Health Canada, EMA, MHRA and TGA. Read the full prescribing information.  

About Cycle  

Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community. Cycle Pharmaceuticals focuses on rare metabolic, rare immunological, and neurological conditions, most of which are genetic conditions. They are a growing company and have recently diversified into oncology, having launched an oncology treatment for patients in the US in October 2025. Cycle Pharmaceuticals is headquartered in Cambridge, UK and has an office in Detroit, Michigan. For more information, please visit www.cyclepharma.com and follow us on Twitter, LinkedIn and Facebook. 

About Inceptua  

Inceptua Early Access partners with pharma and biotech companies to provide truly global early access programs, which allow patients around the world access to potentially life-saving medicines. With offices in 8 countries, and a global warehousing and distribution network, Inceptua Early Access is the preferred partner for many companies in their efforts to bring promising medicines to patients as quickly as possible. Inceptua Early Access is a part of Inceptua Group – global service partner for pharma, delivering clinical trial services, early access programs and distribute medicines worldwide. For more information, please visit www.inceptua.com and follow us on Inceptua Group | LinkedIn

.  

Inceptua Media Contact: 

Morten Grøn 

VP, Corporate Communication and Marketing 

Telephone: +45 2556 4781 

Email: morten.gron@inceptua.com  

Website: www.inceptua.com 

Cycle Media Contact: 

marketing@cyclepharma.com 

Website: www.cyclepharma.com  

References: 

1. Medline Plus (2023) Available at: https://medlineplus.gov/genetics/condition/tyrosinemia/#frequency (Accessed 10 November 2023)
2. Medline Plus (2023) Available at:  https://medlineplus.gov/genetics/condition/alkaptonuria/#frequency (Accessed 14 November 2023)

–ENDS– 

NITYR^® is a registered trademark of Cycle Pharmaceuticals Limited in the United States. 

©2025 Cycle Pharmaceuticals Limited. All rights reserved